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ABSTRACT 
 
 
 
The expanded understanding of the gene families and mechanisms governing 
tumorigenesis pathways has enormous potential for improving current cancer therapies 
and patient prognoses. One such gene family that participates in the regulation of 
tumorigenesis is the tumor necrosis factor alpha-induced protein 8 (TNFAIP8) gene 
family, which is comprised of four members:  TNFAIP8, TNFAIP8L1, TNFAIP8L2, and 
TNFAIP8L3.  The TNFAIP8L1 gene is thought to function as a tumor suppressor, but the 
mechanisms by which it exerts this function have yet to be elucidated. We hypothesize 
that the TNFAIP8L1 protein acts as a tumor suppressor through protein-protein 
interactions that regulate tumor proliferation, migration, and/or angiogenesis. The H1299 
non-small cell lung cancer cell line was engineered to overexpress TNFAIP8L1 protein 
and is being used as an in vitro model to identify putative protein binding partners 
through co-immunoprecipitation and mass spectrometry assays. Apparent interactions 
will be validated by mammalian two-hybrid assays. We anticipated that TNFAIP8L1 
would bind proteins involved in tumorigenesis pathways and that these may reveal new 
avenues of study and hold important clinical relevance in current cancer treatment plans. 
We identified 138 putative protein interactions involving TNFAIP8L1. 
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“Don't you know 
They're talking about a revolution 
It sounds like a whisper 
And finally the tables are starting to turn 
Talking about a revolution 
Yes, finally the tables are starting to turn” 
 – Tracy Chapman 
 
 
 
 
To everyone who is fighting to turn the tables. 
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INTRODUCTION 
 
 
 
Overview 
Cancer is a devastating disease and one of the most clinically relevant illnesses of 
our time. It was the second leading cause of death worldwide in 2015, claiming the lives 
of 8.8 million people (World Health Organization, 2018). There are many burdens 
associated with cancer to the individual, health care systems, and society at-large. 
Approximately 40% of people will be diagnosed with cancer in their lifetime, resulting in 
171.2 deaths per 100,000 people each year (World Health Organization, 2018). The 
leading cause of cancer deaths is lung cancer, which accounts for 25% of all cancer 
deaths. This is more than colon, breast, and prostate cancer combined (American Cancer 
Society, 2018). Despite these overwhelming statistics, there is no cure for cancer. 
There are numerous clinical approaches to treat cancer, but they are not flawless 
and leave room for improvement. In the 1960’s cancer treatments and therapies were 
beginning to be researched and integrative approaches were implemented. During the 
period from 1974 to 1976, the 5-year relative survival rate for all cancers combined was 
50% for adults and 62% for children (National Institute of Health, 2013). Current 
techniques combine elements of medicine and lifestyle changes. A few of the most 
common medical interventions are chemotherapy, radiotherapy, and surgery. 
Chemotherapy uses drugs to kill cancer cells, usually through pills, intravenous access, or 
injection. It is commonly used in conjunction with other therapies like radiotherapy or 
surgery. Radiotherapy uses high doses of radiation to kill cancer and shrink tumors 
(National Cancer Institute, 2017). With the advances in technology, and evidence-based 
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research, there has been an increase in survival rates for adults and children diagnosed 
with cancer. As of 2006, the 5-year survival rates of adults and children diagnosed with 
cancer had increased to 68% and 81%, respectively (National Institute of Health, 2013).  
As improved understanding of the mechanisms behind tumorigenesis and 
technological advances occur, the survival numbers should continue to increase. The 
importance of regular physician visits for screening, diagnosis, therapies, and treatment 
are crucial, but it is beneficial to also consider the importance of prevention. Important 
factors for prevention include diet choice, exercise, and environmental exposure to 
carcinogens. In regard to diet, the American Cancer Society recommends that the amount 
of red meat and processed meat ingested, as well as the number of alcoholic beverages 
consumed, be limited. It is also beneficial to eat adequate amounts of fruits and 
vegetables, as well as switching from refined to whole grains. Adults should engage in 
moderate intensity physical activity for at least 2.5 hrs per week, and children should get 
1 hr of moderate intensity physical activity per day (American Cancer Society, 2016). 
Other things to consider are vaccinations against oncogenic viruses like human 
papillomavirus, as well as limiting exposure to cigarette smoke and ultraviolet radiation 
(Center for Disease Control and Prevention, 2018).  
There are numerous causes of cancer, but most exhibit these six hallmarks of 
acquired biological capabilities: evading apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative potential, 
and the ability to invade tissues and metastasize (Figure 1) (D Hanahan & Weinberg, 
2000). Though this view reduces a complex group of diseases down to a few common 
features, it can be helpful to initially study cellular processes in a microcosm. However, it 
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should also be mentioned that a systems biology approach would be beneficial to 
understanding disease processes since the processes in nature do not exist in a microcosm 
(Fang & Casadevall, 2011).  
Regulation of these processes occurs through many different gene families and 
proteins at work, including the tumor necrosis factor alpha- induced protein 8 
(TNFAIP8) gene family, a relatively new, yet significant family in the regulation of 
inflammation, immunity, and cancer processes (Lou & Liu, 2011). The TNFAIP8 gene 
family is comprised of four members:  TNFAIP8, TNFAIP8L1, TNFAIP8L2, and 
TNFAIP8L3 (Sullivan, Lage, Yoder, Postlethwait, & Kim, 2017). All four gene family 
members encode for proteins that are thought to contain seven alpha helices, with a 
hydrophobic cavity in the center. The cavity is thought to serve as a binding site for co-
factors and molecules interacting with the protein, including lipid second messengers 
Figure 1. The six hallmarks of cancer shown as acquired capabilities of cells 
(Douglas Hanahan & Weinberg, 2011). Cell, Volume 144, Issue 5 , Douglas 
Hanahan,Robert A. Weinberg, Hallmarks of Cancer: The Next Generation, Pages 
646-672, Copyright (2011), with permission (4339050057477) from Elsevier.  
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Table 1. Cancer types previously associated with each gene in the TNFAIP8 gene family. 
required for signaling (Fayngerts et al., 2014; X. Zhang et al., 2009). TNFAIP8 and 
TNFAIP8L2 are involved with immune regulation and inflammation, as well as the 
development and regulation of cancers through roles as either tumor suppressors or tumor 
promoters (Porturas et al., 2015; X. Zhang et al., 2009). The entire TNFAIP8 gene family 
has been linked to cancers ranging from liver and lung cancer to blood and bone cancers 
(Table 1). The TNFAIP8L1 gene is thought to function as a tumor suppressor, but the 
mechanisms by which it exerts this function have yet to be elucidated, leaving potential 
for improving current cancer therapies and patient prognoses with increased 
understanding of the mechanisms (Z. Zhang et al., 2015) . 
 
 
 
 
 
 
 
 
 
Cancer 
 Cancer is a group of diseases where cells in the body divide uncontrollably and 
migrate into surrounding tissues (National Cancer Institute, 2015). It is characterized by 
the six hallmarks of cancer (Figure 1)(D Hanahan & Weinberg, 2000). Cancer is a 
Gene Function  Associated 
Cancers 
 References 
TNFAIP8  Tumor 
Promoter or 
Tumor 
Suppressor 
Stomach, Prostate, 
Ovarian, Lung, 
Blood, Bone 
(Chen et al., 2016; Cheng 
et al., 2015; Eisele et al., 
2007; Liu et al., 2012; 
Xing & Ren, 2016) 
TNFAIP8L1  Tumor 
Suppressor 
Liver, Lung (Wu et al., 2017; Z. 
Zhang et al., 2015) 
TNFAIP8L2  Tumor 
Suppressor 
Stomach, Kidney, 
Liver, Lung, Bone 
(Cao et al., 2013; Deng, 
Feng, & Deng, 2015; Y. 
Li et al., 2015; Peng et 
al., 2016; Zongliang 
Zhang, Qi, Hou, & Jin, 
2013) 
TNFAIP8L3  Tumor 
Promoter 
Lung, Cervix, 
Colon 
(Fayngerts et al., 2014b) 
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disease that arises from changes in genes that control cellular functions such as the cell 
cycle, cell metabolism and cell death. These genetic changes can occur due to many 
environmental and lifestyle factors, as well as a number of unknown reasons. Behaviors 
such as tobacco smoking, use of drugs and alcohol, as well as ultraviolet, and x-ray 
radiation can increase the risk of cancer (National Cancer Institute, 2015). According to 
the World Health Organization, dietary choices, including processed meat and red meat, 
can also cause increased risks of cancer, especially colorectal cancer (Harvard School of 
Public Health, 2015).  
 There are more than 100 types of cancer, ranging from the more common breast, 
prostate, and lung cancers to more rare types such as fallopian tube or heart cancer 
(National Cancer Institute, 2015). Cancer has a massive impact on individuals, families, 
and societies across the globe. In 2012, there were 14 million new cases of cancer and 8.2 
million cancer related deaths. In the United States alone, 1.68 million new cases of cancer 
were estimated for 2016 (“Cancer Statistics - National Cancer Institute,” 2017). These 
statistics place cancer as the second leading cause of death globally and there is currently 
no cure, however, there are numerous treatment options with varying degrees of success 
depending on cancer type (World Health Organization, 2018).  
 The devastation that cancer leaves in its wake is shown in the statistics above, but 
it also takes a toll on the economy of nations, the health care system, and survivors. It is 
estimated that the direct health care costs in the United States for cancer in 2015 reached 
80.2 billion USD and the total economic cost including loss of productivity was 1.16 
trillion USD in 2010 (American Cancer Society, World Health Organization 2018). With 
the number of cases predicted to rise, the economic costs will also rise. The personal and 
6 
 
societal problems associated with cancer are demonstrated in quality of life research 
performed with the help of survivors. One study revealed that there were four major 
domains of life that were altered for survivors including physical well-being, 
psychological well-being, social well-being and spiritual well-being (Mollica, Nemeth, 
Newman, & Mueller, 2015). The survivors noted decreased satisfaction in these areas of 
their life. Physical well-being was marked by dissatisfaction in strength, fatigue pain, and 
the ability to perform daily activities, while psychological well-being was marked by 
issues of anxiety, depression, and fear of recurrence of cancer. The last two domains 
focused on issues relating to hope, inner strength, religion, appearance, relationships, and 
feelings of isolation (Mollica et al., 2015). As scientists, citizens, and humans, there 
should be an emphasis placed on filling knowledge gaps surrounding cancer processes 
and their regulations so that more effective prevention and treatment options can be 
revealed. 
 It is also important to note that a disproportionately high number of cancer cases 
due to preventable diseases such as human papillomavirus and cancer deaths occur in 
low-income and middle-income countries, where prevention, diagnosis and treatment are 
not affordable or available (World Health Organization, 2018). The best way to reduce 
the burden of cancer is to avoid risk factors, vaccinate against cancer associated viruses, 
and get regular screenings. Prevention and early detection are vital to decreasing cancer 
burden (American Cancer Society, 2018a). There are several clinical approaches to treat 
cancer, but they are not perfect and leave room for improvement in patient outcomes, cost 
effectiveness, and specificity of treatment as outlined previously.  There is a promising 
new approach for treatment that relies on individual genomic differences termed 
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personalized medicine. The idea is that each person’s disease has a unique susceptibility 
based on their “genomic blueprint” (“Personalized Medicine,”). It is essential that 
research continues into the mechanisms regulating tumorigenesis and specifically, it is 
important to gain a better understanding of gene families such as the TNFAIP8 gene 
family because they provide greater insight into the mechanisms that govern 
tumorigenesis. Other priorities include increasing political commitment to cancer 
prevention, monitoring cases and costs, as well as developing standard tools and 
treatment methods (World Health Organization, 2018).  
Lung Cancer 
 Cancers that form in tissues of one or both lungs, usually in the cells that line 
airways, are referred to as lung cancer. Lung cancer begins when cells of the lung(s) 
begin to grow and divide abnormally, allowing them to form tumors and spread to other 
areas of the body (American Cancer Society, 2018a, 2018b). There are two major forms 
of lung cancer, non-small cell lung cancer and small cell lung cancer. Non-small cell lung 
cancer makes up 80-85% of all lung cancers, with the other 10-15% being small cell lung 
cancers. Lung cancers are the second most common cancer in men and women, excluding 
skin cancer, (American Cancer Society, 2018b) and are the leading cause of cancer 
deaths in males and females in the United States (Figure 2).  
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Figure 2. Top ten cancer types in males and females in 2017 in the United 
States. Top shows estimated new cases and bottom shows estimated 
deaths. Lung cancer is leading in cancer deaths among both sexes. 
(Siegel et al., 2017). Copyright © 2017, John Wiley and Sons. 
Reprinted by permission from John Wiley and Sons (4339050472934). 
Cancer Journal for Clinicians. Siegel, R. L., Miller, K. D., & Jemal, A. 
(2017). Cancer statistics, 2017. CA: A Cancer Journal for Clinicians, 
67(1), 7–30. https://doi.org/10.3322/caac.21387 
 
 
Smoking cigarettes is the number one risk factor for developing lung cancer and 
is linked to 80-90% of all lung cancers. Smoking increases the risk of developing lung 
cancer by 15 to 30 times. Second-hand smoke is also linked to an increased risk of 
development of lung cancer, especially when children are between the ages of 3-11 years 
old (Center for Disease Control and Prevention, 2017). While the survival rates for most 
cancer diagnoses have increased, lung cancer mortality rates remain high. The 5-year 
survival rate for lung cancer is 18%, which is partially attributable to the fact that most 
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cases are caught in late stages. Over 50% of cases are diagnosed at a stage where 
treatment is rarely effective. Of lung cancer cases diagnosed in late stages, only 4% of 
patients live for more than 5 years (Siegel, Miller, & Jemal, 2017).  This demonstrates the 
need for new and more effective prevention, detection, and treatment protocols. 
Mammalian Cell Culture and NCI-H1299 Cells as Model 
 The NCI-H1299 (H1299) cell line is derived from the lymph node metastasis of a 
non-small cell lung carcinoma in a 43-year-old Caucasian male. The cells do not express 
p53 protein, a known tumor suppressor, due to a homozygous partial deletion. They do 
have the ability to produce neuromedin B, but not gastrin releasing peptide. Both 
neuromedin B and gastrin releasing peptides are the mammalian homologs of bombesin, 
which is a protein used as a tumor marker in small cell lung cancer and stomach cancer 
among others (American Type Culture Collection, 2016; Wang, Knezetic, Schally, Pour, 
& Adrian, 1996). H1299 cells are adherent epithelial cells that can be used as a 
mammalian cell culture model and are suitable for transfections (American Type Culture 
Collection, 2016). 
 Cell culture can be used as an in vitro or in vivo model, but is generally used in 
two-dimensional (2D) cell culture as an in vitro model. To be used as an in vivo model, 
H1299 cells are typically transplanted into recipient animal models such as mice. These 
xenotransplantation models are often used as an initial step in research to understand how 
cancer cells of various types behave in a live organism (Giovanella, Yim, Stehlin, & 
Williams, 1972). A possible bridge between 2D in vitro studies and in vivo studies are 
those of three-dimensional (3D) cell culture. In typical 2D cell culture, cells are cultured 
on flat plastic flasks, or dishes in medium suited for the particular cells to grow in. The 
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cells are then grown in a monolayer and passaged, until used for further experimentation. 
This method has benefits of being fast, easy, and cost-effective; however, it also has its 
drawbacks. Cells grown in 2D culture exist in a monolayer composed of growing and 
dividing cells, where all dead cells have detached from the culture vessel. The dead cells 
are then removed with each passaging. Also, cells grown in 2D models are more 
stretched out and flat than they normally grow leading to an abnormal cell morphology. 
This abnormal morphology could have influences over processes of interest such as cell 
proliferation, gene expression, and protein expression. Overall, these cells may not 
behave as they would in vivo (Edmondson, Broglie, Adcock, & Yang, 2014). On the 
other hand, 3D cell culture is becoming more popular as it has all the benefits of 2D cell 
culture and being an in vitro model, however it better mimics the microenvironments of 
in vivo studies. The cells are cultured using hydrogel or an agar layer to allow cells to 
grow in all directions. This model allows cells to interact with each other in a way more 
accurate to in a live model. It is important to note that the 3D system also has drawbacks 
in the ways that you have cells growing together, but they do not possess vascular 
systems so the passage of waste, nutrients, and oxygen are only carried out by diffusion. 
This limits the size of spheroids that can be grown and what types of cells can be used 
(Edmondson et al., 2014). 
Overall, cell culture allows the cells removed from various animal or plant tissues 
to be grown in artificial media. After cells are isolated and grown up on artificial media 
to a point where they must be passaged, they become cell lines. Cell lines are 
immortalized through acquisition of genetic mutations that allow them to grow and these 
cell lines can then be continually passaged and used in research. The culture conditions 
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for each cell type vary, but they all require essential nutrients such as amino acids, 
carbohydrates, and gas exchange. Cell culture is one of the most important tools available 
to study biochemical processes and allows for results to consistent and reproduced (Cell 
Culture Basics Handbook, 2016). It also provides the advantage of being relatively easy, 
and cost effective. 
 In this study, the H1299 cell line was used as a 2D model, where a monolayer of 
cells is grown in a tissue culture flask or dish and then passaged for continuation of the 
cell line.  
TNFAIP8 Gene Family 
 The tumor necrosis factor-alpha-induced protein 8 (TNFAIP8) gene family is a 
recently discovered family that has been found to be involved in regulation of 
tumorigenesis, inflammation, and immunity (Lou & Liu, 2011). The four members 
TNFAIP8, TNFAIP8L1, TNFAIP8L2 , and TNFAIP8L3 all encode for proteins with a 
unique structure that includes seven alpha helices surrounding a central hydrophobic 
cavity (Sullivan et al., 2017). The gene family members TNFAIP8 and TNFAIP8L2 are 
activated by TNF-α in times of environmental stress. Since discovery of this gene family, 
there have been many studies to elucidate structure and function of the members, 
however TNFAIP8L1 still remains uncharacterized. TNFAIP8 functions as a tumor 
promoter or tumor suppressor, depending on the splicing variant (Lowe et al., 2017) and 
has been associated with lung, blood and bone cancers among others. TNFAIP8L1 
functions as a tumor suppressor and has been linked to liver and lung cancer, but the 
mechanism by which it exerts this function has yet to be elucidated. TNFAIP8L2 is also 
classified as a tumor suppressor and has also been linked to liver and lung cancer. The 
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Figure 3. Proposed mechanism by 
which TNFAIP8 splice variant 2 
performs its function as a tumor 
promotor. 
 
last member, TNFAIP8L3, has been shown to function as a tumor promoter and is 
associated with lung, cervix, and colon cancers (Table 1). 
TNFAIP8 
TNFAIP8, also known as SSC-S2, GG2-1, 
and MDC-3.13, is an oncogenic protein and 
apoptotic  regulator (X. Zhang et al., 2009). It was 
the first gene family member described and is one 
of the most well characterized genes in the family 
along with TNFAIP8L2. It has been shown to act as 
either a tumor promotor or tumor suppressor 
depending on the splice variant and cell type 
affected (Kumar et al., 2004; Lowe et al., 2017). 
One study showed that variant 2 is overexpressed in many human cancers including lung 
adenocarcinoma, lung squamous cell carcinoma, and hepatocellular carcinoma, where 
variant 1 of TNFAIP8 is downregulated and variants 3,4,5 and 6 are expressed at very 
low levels (Lowe et al., 2017). The proposed mechanism by which variant 2 promotes 
cancer is through p53 repression, in effect cancelling out its ability to induce apoptosis 
and inhibit tumorigenesis. TNFAIP8 has also been hypothesized to protect cells against 
apoptosis through inhibiting Rac1 (Figure 3). The TNF-a cytokine activates the tumor 
necrosis factor receptor (TNFR), which activates Rac1 and NF-kB. Rac1 is responsible 
for promoting cell death through the ultimate promotion of reactive oxygen species 
(ROS), but the TNFR also activates NF-kB which increases TNFAIP8 expression 
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allowing it to inhibit Rac1 and therefore stopping the production of ROS and cell death 
(Porturas et al., 2015).  
TNFAIP8L1 
TNFAIP8L1 is expressed in many tissues, and a study in mice revealed that 
TNFAIP8L1 was found in tissues ranging from neurons in the brain, muscle tissue, and 
hepatocytes, as well as many cells of epithelial origin. This is important because 
epithelial tissues play a role in many processes such as absorption, secretion, and 
immunity (Cui et al., 2011). TNFAIP8L1was shown to induce apoptosis in hepatocellular 
carcinoma cells (HCC) by negatively regulating Rac1 and altering down-stream pathway 
activations (Z. Zhang et al., 2015). This is comparable to the proposed mechanism by 
which TNFAIP8 carries out its functions.  TNFAIP8L1 has also been shown to inhibit the 
growth of lung cancer, with low levels expressed in tumor tissue (Wu et al., 2017). 
Decreased levels of TNFAIP8L1 have been correlated with poor patient survival and have 
led to the hypothesis that it can be used as a negative prognostic indicator for lung cancer 
patients (Wu et al., 2017). To fully understand the function of TNFAIP8L1, we must 
understand the structure. It is hypothesized that the structure of TNFAIP8L1 is very 
similar to TNFAIP8L2, which is composed of 7 anti-parallel alpha helices. There is also a 
central hydrophobic cavity which is a potential site for co-factor binding and may play a 
role in immune homeostasis (X. Zhang et al., 2009). Based on this known structure of 
TNFAIP8L2 and the comparison of each amino acid residue among the gene family 
members (Figure 4,5)(Sullivan et al., 2017), it is suggested that TNFAIP8L1 has a 
similar structure as described for TNFAIP8L2.  
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TNFAIP8L2 
TNFAIP8L2 along with TNFAIP8 is the most well characterized of the gene family 
members. A study in 2009 revealed a previously uncharacterized fold that differed from 
the prior hypothesis that TNFAIP8L2 had a death effector domain (DED) important to 
the execution of its function as a tumor suppressor. This fold was discovered following 
the elucidation of a high-resolution crystal structure of TNFAIP8L2. It also revealed a 
large, central hydrophobic cavity that is most likely the site for co-factor binding and 
Figure 4. (A) Comparison of amino acid sequences encoded for by each member 
of the TNFAIP8 gene family using Clustal Omega analysis. (B) Quantification 
of sequence identity between gene family members reported as percentage of 
shared amino acid sequence. Figure reprinted under the terms of the Creative 
Commons Attribution License. PLOS ONE. © 2017 Sullivan et al. 
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Figure 5. (a)The overall structure of TNFAIP8L2 
showing all six alpha helices. (b) TNFAIP8L2 
topology is different than that of the DED domain 
(X. Zhang et al., 2009). Reprinted by permission 
from Springer Nature: Zhang, X., Wang, J., Fan, C., 
Li, H., Sun, H., Gong, S., … Shi, Y. (2009). Crystal 
structure of TIPE2 provides insights into immune 
homeostasis. Nature Structural and Molecular 
Biology, 16(1), 89–90. 
https://doi.org/10.1038/nsmb.1522 
 
phosphoinositide second messenger 
binding (Figure 5) (Fayngerts et al., 
2014b; X. Zhang et al., 2009).  
TNFAIP8L2 plays an important role 
in immune homeostasis and has also 
been shown to inhibit human 
hepatocellular carcinoma metastasis 
in HCC-derived cells lines. A study 
of 112 patients showed that loss 
or reduction of TNFAIP8L2 in 
primary HCC tissues led to 
greater metastasis. It was 
discovered that the cause is that 
TNFAIP8L2 inhibits the migration and invasion of cancer cells through inhibition of 
Rac1(Cao et al., 2013). This targeting of Rac1 is consistent with studies performed using 
TNFAIP8 and TNFAIPL1 and shows a similarity in execution of tumor suppression. 
 
TNFAIP8L3 
TNFAIP8L3 is a cytoplasmic protein that is expressed in various mouse and 
human tissues, but generally restricted to cell types of epithelial origin. High levels have 
been detected in the digestive tract, the islets of the pancreas, and breast duct epithelial 
cells (Cui et al., 2015). The protein expression similarities between human and mice may 
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be due to the homologous sequences they share and this trend of tissue specific 
expression has been shown in studies of other gene family members (Chen et al., 2016; 
Cui et al., 2011, 2015). TNFAIP8L3 has been shown to function as the transfer protein of 
phosphoinositide second messengers that promote cancer. Similar to the structure of 
TNFAIPL2, it has a large hydrophobic cavity that can bind lipid second messengers 
(Fayngerts et al., 2014b). In human cancers associated with TNFAIP8L3 upregulation 
subsequent knockout of TNFAIP8L3 results in decreased tumorigenesis. Conversely in 
cell culture, when TNFAIP8L3 expression is forced, tumorigenic effects are increased 
(Fayngerts et al., 2014b).  
Interactomics 
Interactomics is the study of protein-protein interactions and their implications 
using scientific experimentation and bioinformatics for analysis. The study of protein 
interactions is necessary for understanding cellular function and more complex pathways 
where proteins are interacting (Dammeyer & Schobert, 2010). There are many different 
techniques for studying and/or validating these interactions including co-
immunoprecipitation coupled with mass spectrometry, yeast two-hybrid assays, 
mammalian two-hybrid assays, proximity ligation assays, and bimolecular fluorescence 
complementation (Table 2).  
Utilizing mass spectrometry based proteomics allows the protein itself to be used 
to isolate its binding partners. In the past, yeast two hybrids were used, but the 
advantages of co-immunoprecipitation with mass spectrometry analysis include that 
multi-component complexes can be isolated with only one step, and that it utilizes the 
protein of interest in its processed form (Free, Hazelwood, & Sibley, 2009). Data indicate 
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that mass spectrometry coupled with co-immunoprecipitation is a quick, safe, and 
efficient way of identifying protein-protein interactions. It is one of the best tools 
available for elucidating previously unknown protein partners due to the volume of data 
and interactors that can be processed (Moresco, Carvalho, & Yates, 2010). 
 
 
Mass Spectrometry 
Mass Spectrometry is an analytical technique that separates ions based on their 
mass-to-charge ratio. Two particles with the same mass-to-charge ratio will separate in 
Interactomics Technique Advantages Disadvantages 
Co-immunoprecipitation 
and Mass Spectrometry 
Isolation of protein 
complexes, protein of 
interest is in processed 
form, large scale, time 
effective 
Not all interactors are true 
interactors, not able to 
resolve interactors in 
complexes, does not 
validate specific 
interactions 
Mammalian Two-Hybrid 
Assay 
Fast, inexpensive, flexibility 
of interactors 
Direct interactors only, 
some proteins can be toxic 
to host cells 
Yeast Two-Hybrid Assay Eukaryotic form, can be 
scaled up easily 
Direct interactors only, 
interacting proteins must 
move to the nucleus, 
proteins not in natural 
environment, issues with 
post translational 
modifications occurring 
properly 
 
Proximity Ligation Assay Easy, sensitive, can closely 
mimic natural environment 
for the protein 
Direct interactors only, 
increased cost, increased 
time for result output 
Bimolecular Fluorescence 
Complementation 
Allows for tracking of 
interactions over time and 
changing conditions, 
sensitive, can detect direct 
and indirect interactors 
Requires expensive 
equipment, not best choice 
for direct interactions 
Table 2. Summary of the advantages and disadvantages of the major interactomics techniques used for 
studying and validating protein-protein interactions. 
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the same way. The first step is ionization of the sample, where electrons are removed to 
give the sample a positive charge. Post ionization, the ions are accelerated to a uniform 
kinetic energy and subjected to a magnetic field. Deflection of the ions as they pass 
through the magnetic field will vary based on their size and charge, giving a mass-to-
charge ratio. Smaller ions and ions with the greatest charge are deflected at a higher rate. 
The beam of ions passes through a detector that allows a spectral fingerprint to be 
recorded (Breci, 2017). The spectral data are reported as relative abundance versus mass-
to-charge ratio. These are then entered into a spectral database for analysis and 
determination of protein identity (Cottrell, 2011). 
Instrument Advantages Disadvantages 
Quadrupole Mass 
Analyzer 
 
Relatively cheap and 
fast, reproducible results 
Lower resolving power, 
Time of Flight Mass 
Analyzer 
 
Fast, sensitive, increased 
molecular weight range-
useful for biological 
samples 
Limited dynamic range 
Quadrupole Ion Trap 
Mass Analyzers 
 
Qualitative work (i.e 
protein identification), 
sensitive, high resolution 
Quantitative work, not 
optimal for work with 
masses below 100 Da, 
Low scan rate 
 
 
 
 
  
Table 3. Advantages and disadvantages of widely used mass analyzers. 
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MATERIALS AND METHODS 
 
 
 
Cell Culture 
 NCI-H1299 Cell Line was grown in Roswell Park Memorial Institute (RPMI-
1640) Medium (Corning®, Corning, New York), supplemented with 10% Fetal Select 
serum (Atlas Biologicals, Fort Collins, Colorado). The cells were grown in T-25 tissue 
culture flasks and incubated at 37°C, 5% CO2. Cells were passaged every 2-3 days at 80-
90% confluency. 
Creation of a Stable Gene Overexpression 
Antibiotic Sensitivity Curve 
An antibiotic sensitivity curve assay was performed using the NCI-H1299 Cell 
Line to determine an optimal selection concentration of Geneticin™ selective antibiotic 
(G418 Sulfate – Gibco County Dublin, Ireland) to be used for selection of successful 
transformants.  Cells were plated at 50,000 cells/well in a 12 well plate and grown 
overnight in RPMI-1640 medium (Corning®). Twenty-four hours post-plating; varying 
Geneticin™ selective antibiotic (G418 Sulfate – Gibco) concentrations were added to the 
wells. Concentrations ranged from 0.0 mg/mL (Control) to 1.2 mg/mL. RPMI-1640 
medium was replaced every 48 hrs with cell cytopathic effects and cell death observed 
every 24 hrs for 14 days for the lowest concentration that killed 100% of cells.  
Stable Line Generation - Transfections 
One day prior to transfection, cells were plated at 50,000 cells per well in a 24 
well plate in RPMI-1640 (Corning®) medium and 10% Fetal Select serum (Atlas 
Biologicals). The next day, NCI-H1299 cells were transfected with 0.5 ug pcDNA3.1+/c-
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(k)-DYK empty vector (GenScript, Piscataway, New Jersey), pcDNA3.1+/c-(k)-HPRT-
DYK (GenScript) or pcDNA3.1+/c-(k)-TNFAIP8L1-DYK (GenScript) using DNA-In® 
transfection reagent (Molecular Transfer Inc., Gaithersburg, Maryland) according to 
manufacturer’s instructions. The transfection process forced the cells to express 
TNFAIP8L1 or HPRT1 respectively, while the empty vector transfection was used as a 
control to verify that the plasmid itself or the transfection method was not cytotoxic to 
our cells. In the pcDNA3.1+/c-(k)-DYK plasmid, the DYK portion encodes for a FLAG 
tag which can be used to isolate the protein and protein interests of complexes through 
utilization of anti-FLAG antibodies. In the twenty-four hours-post-transfection, medium 
replaced with fresh RPMI-1640 (Corning®) medium and 10% Fetal Select serum (Atlas 
Biologicals). Forty-eight hours-post-transfection, cells were trypsinized with 0.25% 
trypsin EDTA (1x) (Gibco) and transferred to T-25 flasks. Seventy-two hours-post-
transfection, RPMI-1640 medium containing 10% Fetal Select serum (Atlas Biologicals) 
and 0.75 mg/mL Geneticin™ selective antibiotic (G418 Sulfate-Gibco) was added to 
cells to select for successful transformants. Future passages of transfected cells used 
RPMI-1640 medium with 10% Fetal Select serum (Atlas Biologicals) and 0.75 mg/mL 
Geneticin™(Gibco) in order to continue selection of successful transformants.  
Transient Gene Overexpression 
 NCI-H1299 Cells were used at 90% confluence in T-25 flasks containing RPMI-
1640 (Corning®) medium and 10% Fetal Select serum (Atlas Biologicals). NCI-H1299 
cells were transfected with 5.0 ug pcDNA3.1+/c-(k)-DYK empty vector (GenScript), 
pcDNA3.1+/c-(k)-HPRT-DYK (GenScript) or pcDNA3.1+/c-(k)-TNFAIP8L1-DYK 
(Genscript) using DNA-In® transfection reagent (Molecular Transfer Inc.) according to 
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manufacturer’s instructions. All flasks were co-transfected with 1.0 ug 
pAdVAntage™(Promega, Madison, Wisconsin), to increase protein expression of interest 
by increasing initiation of translation. Twenty-four hours-post-transfection, medium was 
replaced with new RPMI-1640(Corning®) medium and 10% Fetal Select (Atlas 
Biologicals). Forty-eight hours-post-transfection cells were lysed for co-
immunoprecipitation. 
Co-Immunoprecipitation 
In order to determine putative protein interactors, TNFAIP8L1 and the interacting 
proteins were isolated from the cell lysate by co-immunoprecipitation. H1299 cells stably 
expressing TNFAIP8L1and HPRT1 were lysed in Pierce™ IP Lysis Buffer 
(ThermoFisher Scientific, Waltham, Massachusetts) containing Halt™ protease and 
phosphatase inhibitors (ThermoFisher Scientific) for thirty mins with constant agitation at 
4°C on a rotator. Following thirty-minute lysis, lysate was microcentrifuged for twenty 
mins at12,000 RPM at 4°C. Supernatant was added to Anti-FLAG® M2 Magnetic Beads 
(Sigma-Aldrich, St. Louis, Missouri) and incubated overnight with constant agitation at 
4°C on a rotator. Beads were washed with TBST (Tween-20 at 0.05%) and eluted in 2x 
Laemmli sample buffer (Bio-Rad, Hercules, California) containing 5% 2-
mercaptoethanol (2-ME) and boiled at 100°C for three mins. Eluate was used for western 
blot analysis and/or mass spectrometry analysis. 
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Western Blots 
Western blots were performed to determine that TNFAIP8L1 and HPRT1 were 
present in our transfected cells and therefore suitable for the next steps. Eluate in 2x 
loading dye with 5% 2-ME was loaded on Mini-PROTEAN© TGX™ Pre-Cast gels (Bio-
Rad). The PAGE gel was run in 1x Tris/Glycine/SDS Buffer (Bio-Rad) at 150 volts for 
30 to 50 mins. Chameleon Duo Pre-Stained Protein Ladder was used as a standard (LI-
COR Biosciences, Lincoln, Nebraska). Proteins were transferred to a nitrocellulose 
membrane in 1x Turbo Transfer Buffer using a Trans-Blot® Turbo™ Transfer System 
(Bio-Rad), according to the manufacturer’s protocol. REVERT™ Total Protein stain (LI-
COR) was used according to manufacturer’s protocols prior to blocking blots in nonfat 
dried milk for visualization of potential protein interactors pulled out during co-
immunoprecipitation. Blots were imaged on the Odyssey® CLx Infrared Imaging System 
(LI-COR). Membrane was then blocked in 5% non-fat dried milk in TBST (0.1% Tween 
Figure 6. Co-immunoprecipitation schematic beginning with lysis of cells through incubation with Anti-
FLAG© M2 Magnetic Beads (Sigma), wash steps and elution for western blot and mass spectrometry 
analysis. 
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20) for 60-90 mins before incubation with rabbit DYKDDDDK tag polyclonal antibody 
(2 ug/mL) (Invitrogen, Carlsbad, California) overnight at 4°C on a nutator (Fisher 
Scientific, Hampton, New Hampshire). The nitrocellulose membrane was rinsed two 
times with TBST and then washed three times with TBST for 5 mins each on a rocking 
platform. Post washing, blot was incubated with IRDye®800CW Donkey anti-Rabbit 
secondary antibody (70 ng/mL) (LI-COR) for 1 hr in the dark at room temperature on a 
rocker. Blot was washed three times with TBST and two times with TBS before imaging 
on the Odyssey® CLx Infrared Imaging System (LI-COR). 
Mass Spectrometry 
 Protein identification was achieved through Ultra-performance liquid 
chromatography-tandem mass spectrometry on the Q-Exactive HF-X quadrupole-
Orbitrap mass spectrometer (ThermoFisher Scientific). Protein identification completed 
using Comet and Tandem spectral libraries. Samples were processed by Dr. Brian 
Balgley at Bioproximity (Chantilly, Virginia). 
Sub-cloning 
PCR amplifications of TNFAIP8L1, DVL3 and FBXW5 inserts were performed 
in 50 uL reactions with (1x) Q5® reaction buffer (New England BioLabs, Ipswich, 
Massachusetts), 200 nM dNTP mixture, 0.02 U/uL Q5® polymerase (New England 
BioLabs), 1.0 ng of template and 0.5 uM of respective primers (Table 4). PCR 
amplification of TNFAIP8L1, DVL3 and FBXW5 was run at a reaction protocol of 
incubation at 98°C for 30 seconds, followed by 20 cycles of 98°C for 10 seconds, 60°C 
for 15 seconds, 72°C for 75 seconds, and then 72°C for 5 mins and held at 12°C. 
 
24 
 
Insert  Forward Primer (BamHI) Reverse Primer (NotI) 
TNFAIP8L1 ACGTAT GGATCCGT ATGG 
ACACCTTCAG CACCAAG 
ACGTAT GCGGCCGC 
TCAGAGGCTGCCCTCGTCCAG  
 
FBXW5 ACGTAT GGATCCGT 
ATGGACGAGGGCGGCACGCC
  
ACGTAT GCGGCCGC 
TCAGCGCCTCTGGCTGGCAAG 
 
DVL3 ACGTAT GGATCCGT 
ATGGGCGAGACCAAGATCAT
  
ACGTAT GCGGCCGC 
TCACATCACATCCACAAAGAA 
 
Table 4. Forward and reverse primers used in PCR amplification of inserts TNFAIP8L1, 
DVL3 and FBXW5. 
 
 Restriction digestion of PCR products was performed using BamHI and Not1 to 
create compatible ends for ligations with pACT and pBIND vectors used in mammalian 
two-hybrid assays.  Similarly, pACT and pBIND were subjected with restriction 
digestions with BamHI and NotI.   Ligations were performed to generate fusion proteins 
with all plasmids and inserts (Table 5) with 50 ng vector and a 1:3 vector to insert ratio. 
Nuclease free water, 10x T4 ligase buffer (New England BioLabs), 50 ng vector, insert 
and T4 DNA ligase (New England BioLabs) were combined and ligation was run at RT 
for 1 hr. Ligations were then immediately used in transformations. One Shot™ Top10 
competent Escherichia coli cells (ThermoFisher Scientific) were transformed and plated 
on LB-AMP (100 ug/mL) plates for selection of successful transformants. Colonies were 
picked and grown in LB-AMP liquid media (100ug/mL) overnight at 37°C with constant 
shaking. Plasmid DNA was isolated after 16 hrs using QIAprep® Spin Miniprep Kit 
(QIAGEN, Hilden, Germany). Glycerol stocks were made of all mini preps by adding 1 
part of respective miniprep to 1 part 65% glycerol (0.1M MgSO4, 0.025 M Tris-HCl, pH 
8.0) and mixing well, then placing in -80°C.   
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The success of ligation was then determined for each individual transformant by 
separating the restriction digestion on a 1.5% agarose gel to identify correct restriction 
digestion pattern. The plasmids (Table 5) were then analyzed for correct, in-frame 
sequence by DNA sequencing (University of Maine Sequencing Facility) with T7 EEV 
primer (Promega). 
 
 
Subcloning of Mammalian-Two Hybrid Assay Plasmids 
 One Shot™ Top10 competent Escherichia coli cells (ThermoFisher Scientific) 
were transformed using the pACT, pBIND and pG5luc vectors from the CheckMate™ 
Mammalian Two-Hybrid System (Promega) and plated out onto LB-AMP (100 ug/mL) 
plates for selection of successful transformants. Colonies were picked of successful 
transformants and grown in LB-AMP liquid medium (100 ug/mL) overnight at 37°C with 
constant shaking. Plasmid DNA was isolated after 16 hrs using QIAprep® Spin Miniprep 
Kit (QIAGEN, Hilden, Germany). Glycerol stocks were made of all minipreps by adding 
one part of respective miniprep to one part 65% glycerol (0.1M MgSO4, 0.025 M Tris-
HCl, pH 8.0) and mixing well, then placing stocks in -80°C. 
Plasmids Fusion Proteins 
Positive Control: pACT-MyoD and 
pBIND-ID  
Encodes for VP16-MyoD and GAL4-Id 
fusion proteins, respectively. 
Negative Control: pBIND and pACT Encode for no fusion proteins 
pACT-TNFAIP8L1 Encodes for VP16-TNFAIP8L1 
pACT-DVL3 Encodes for VP16-DVL3 
pACT-FBXW5 Encodes for VP16-FBXW5 
pBIND-TNFAIP8L1 Encodes for GAL4-TNFAIP8L1 
pBIND-DVL3 Encodes for GAL4-DVL3 
pBIND-FBXW5 Encodes for GAL4-FBXW5 
Table 5. Summary of plasmids and fusion constructs used in mammalian two-hybrid 
assay. 
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Plasmids pcDNA3-myc3-FBXW5 (Addgene, Cambridge, Massachussets), 
pDONR223-DVL3-WT (Addgene) and pcDNA3.1+/c-(k)-TNFAIP8L1-DYK 
(GenScript) were quadrant streaked onto LB AMP plates (100 ug/mL). Colonies were 
picked and grown up in LB AMP liquid medium (100 ug/mL) overnight at 37°C with 
constant shaking. Plasmid DNA was isolated after 16 hrs using QIAprep® Spin Miniprep 
Kit (QIAGEN). Glycerol stocks were made of all minipreps by adding one part of 
respective miniprep to one part 65% glycerol (0.1M MgSO4, 0.025 M Tris-HCl, pH 8.0) 
and mixing well, then placing stocks in -80°C. 
Mammalian Two-Hybrid Transfections 
 H1299 Cells were plated at 5,000 cells/well in a white 96 well plate and grown 
overnight in RPMI-1640 with 10% Fetal Select serum (Atlas Biologicals). The next day, 
cells were transfected using DNA-In™ (Molecular Transfer Inc.) and respective pACT 
and pBIND experimental plasmids (75 ng) and pG5luc (50ng) according to 
manufacturer’s protocols (Promega) (Table 5). Transfected cells were placed in 
incubator at 37°C, 5% CO2. Twenty-four hours later medium was replaced with fresh 
RPMI-1640 medium (Corning®). Forty-eight hours-post-transfection; cells were used for 
Dual-Luciferase® Reporter Assay (Promega). 
Dual Luciferase Assay 
 
Dual-Luciferase® Reporter Assay (Promega) Reagents were prepared according 
to the manufacturer’s recommendations. Passive lysis buffer (PLB) was diluted to (1x) by 
mixing 1 volume (5x) PLB and 4 volumes distilled water. Luciferase assay reagent II 
(LARII) was prepared by re-suspending lyophilized luciferase assay substrate in 
luciferase assay buffer II. Stop & Glo reagent was prepared by adding 200 uL of (50x) 
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Stop & Glo Substrate to 10 mL of Stop & Glo Buffer in a glass vial. These volumes were 
adequate for 100 assays. 
Forty-eight hours-post-transfection, RPMI-1640 medium (Corning®) with 10% 
Fetal Select serum (Atlas Biologicals) was removed from the H1299 cells and cells were 
washed with (1x) Phosphate Buffered Saline (PBS). H1299 cells were lysed with (1x) 
PLB for 15 mins at room temperature, on a rocker. Following lysis, cells were stored at -
20°C. Forty-eight hrs later, cells were plated into a white 96 well plate for completion of 
the protocol. The standard Dual-Luciferase® Reporter Assay (Promega) protocol was 
performed according to manufacturer’s protocol using a GloMax® 96 Microplate Dual 
Injector Luminometer (Promega). Relative interaction values reported are ratios of firefly 
luciferase to Renilla luciferase. 
 
 
 
 
 
 
Figure 7. Schematic diagram of mammalian two-hybrid assay. Two genes of interest were 
cloned into the pACT and pBIND vectors to express proteins that have potential for 
interaction. Fusion proteins were created expressing VP16-TNFAIP8L1, GAL4-DVL3, 
GAL4-FBXW5 and VP16-DVL3, VP16-FBXW5, GAL4-TNFAIP8L1. The pG5luc Vector 
contains GAL4 binding upstream of the firefly luciferase gene. The GAL4 and VP16 fusion 
proteins were transfected along with the pG5luc Vector into H1299 cells. Two days post 
transfection; the cells were lysed and analyzed using the Dual-Luciferase® Reporter Assay 
System. The firefly luciferase production is relative to the protein-protein interaction 
occurring, however there is also Renilla luciferase production encoded for by the pBIND 
vector. This production allows for normalization of results to account for number of cells, 
transfection efficiency and comparison across all constructs. 
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RESULTS 
 
 
 
Optimal selection concentration of Geneticin™ is 0.75 mg/mL in H1299 cells. 
An antibiotic sensitivity assay was performed using the NCI-H1299 Cell Line to 
determine an optimal selection concentration of Geneticin™ selective antibiotic (Gibco).  
Cells were plated at 50,000 cells/well in a 12 well plate and grown overnight in RPMI-
1640 medium (Corning®). Twenty-four hours post-plating; varying Geneticin™ selective 
antibiotic (G418 Sulfate – Gibco) concentrations were added to the wells. Concentrations 
ranged from 0.0 mg/mL (Control) to 1.2 mg/mL. RPMI-1640 (Corning®) medium was 
replaced every 48 hrs with cell cytopathic effects and cell death observed every 24 hrs for 
14 days for the lowest concentration that killed 100% of cells. The concentration was 
determined to be 0.75 mg/mL. 
TNFAIP8L1-FLAG Overexpressed in H1299 cells. 
An antibiotic sensitivity assay was performed using the NCI-H1299 Cell Line to 
determine an optimal selection concentration of Geneticin™ selective antibiotic to be 
0.75 mg/mL. H1299 cells were transfected with pcDNA3.1+/c-(k)-DYK empty vector 
(GenScript), pcDNA3.1+/c-(k)-HPRT-DYK (GenScript) or pcDNA3.1+/c-(k)-
TNFAIP8L1-DYK. Verification of successful stable TNFAIP8L1 overexpression in 
H1299 lung cancer cell line was completed through western blot analysis. Results 
indicate that the TNFAIP8L1 transfection was successful with the presence of a band 
around 18 kDa. The empty-FLAG negative control showed a band that was unexpected, 
around 12.5 kDa. The HPRT1-FLAG positive control for non-specific binding was 
visualized as a band around 19 kDa (Figure 8). The bands were seen at lower molecular 
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weights than we predicted based on the sizes of the proteins. TNFAIP8L1 was expected 
to be seen around 20.8 kDa and HPRT1 around 25 kDa.
 
 
 
Protein Interactions occurring with TNFAIP8L1. 
To visualize all proteins bound to the nitrocellulose membrane and consequently 
interactors pulled out during co-immunoprecipitation with TNFAIP8L1, 
REVERT™ Total Protein Stain was used prior to blocking blot in non-fat dried milk. This 
was used as an indicator that there was enough protein for detection by mass 
spectrometry. Coomassie Blue staining of SDS-PAGE gel, or fluorescent staining and 
visualization could have also been performed to visualize total proteins. Imaging at 700 
nm showed interactors were present with both controls (empty vector and HPRT1), as 
well as TNFAIP8L1-FLAG (Figure 9). The size of putative interactors has a range from 
approximately 15-125 kDa. The heavy and light chains of the anti-FLAG M2 antibody 
Figure 8. Lane 1 (left) showing immunoprecipitation 
of a non-specific protein in control cells. Lane 2 
(middle) shows presence of TNFAIP8L1 in H1299 
Transfected cells. Lane 3 (right) shows successful 
transfection of HPRT1 into H1299 Cell Line. 
Chameleon Duo Pre-stained Protein Ladder was used 
as a standard. H1299 cells stably expressing 
TNFAIP8L1-FLAG and HPRT1-FLAG were lysed 
and incubated with Anti-FLAG© M2 Magnetic Beads 
overnight at 4°C. Beads were washed three times with 
TBST (Tween-20 to 0.05%) before elution in 2x 
Laemmli sample buffer containing 5% 2-
mercaptoethanol. Eluate in 2x loading dye with 5% 2-
ME was loaded on Mini-PROTEAN© TGX™ Pre-
Cast gel. Gel was run in 1x Tris/Glycine/SDS Buffer 
(Bio-Rad) at 150 volts for thirty mins. Membrane 
blocked in 5% non-fat dried milk in TBST (0.1% 
Tween 20) for 60-90 mins before incubation with anti-
FLAG antibody (1:500) overnight at 4°C. Membrane 
was washed three times with TBST for 5 mins each 
before incubation with anti-rabbit secondary antibody 
(1:15,000) for 1 hr. Blot imaged on the Odyssey® CLx 
Infrared Imaging System (LI-COR).  
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are seen separately due to the presence of 2-mercaptoethanol breaking the antibody 
chains apart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNFAIP8L1 has 138 putative protein interactors in H1299 lung cancer cell line model. 
Identification of putative protein interactors with TNFAIP8L1 was performed 
utilizing co-immunoprecipitation and mass spectrometry. Co-immunoprecipitation was 
performed using Anti-FLAG© M2 Magnetic Beads. Beads were frozen and subsequently 
eluted with FLAG peptide. Eluate was analyzed using Ultra-performance liquid 
chromatography-tandem mass spectrometry on the Q-Exactive HF-X quadrupole-
Orbitrap mass spectrometer (ThermoFisher) by Bioproximity. Protein identification was 
completed using Comet and Tandem spectral libraries. There were 561 unique genes 
encoding proteins that were interacting with our negative control (empty) and 181 unique 
Figure 9. REVERT™ Total Protein Stain was used prior to blocking blots in 
non-fat dried milk for visualization of protein interactors pulled out during co-
immunoprecipitation. Blot imaged on Odyssey® CLx Infrared Imaging 
System (LI-COR). Bands indicate total protein. TNFAIP8L1-FLAG in lane 3 
shows proteins pulled out with TNFAIP8L1 during co-immunoprecipitation.  
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genes encoding proteins that were interacting with our HPRT1 control for non-specific 
binding. There were 31 genes encoding proteins that were interacting with both 
TNFAIP8L1 and HPRT1, and 92 genes encoding proteins that were interacting with all 
three. There were 138 unique genes identified that encode for proteins interacting solely 
with TNFAIP8L1 (Figure 10, Table 6, Supplementary Table 1). The genes play 
various roles in biological processes according to gene ontology analysis with the 
PANTHER classification system. Of the 138 genes, 27% encode proteins involved in 
cellular processes including cell recognition and cell cycle regulation (Figure 11). A web 
of genes was analyzed to show protein interactions using NetworkAnalyst to visualize 
interactors as they relate to specific processes and each other (Figure 12a). Interactors 
involved in cell cycle regulation are shown in blue (Figure 12a) and pulled out for better 
visualization (Figure 12b). The genes are shown in their biological networks to narrow in 
on their relationships and commonalities in functions. 
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Oliveros, J.C. (2007-2015) 
Venny. An interactive tool for 
comparing lists with Venn's 
diagrams. 
http://bioinfogp.cnb.csic.es/to
ols/venny/index.html 
Figure 10. Venn diagram representing number of genes that encode for proteins interacting with 
the proteins of interest. Green represents the empty-FLAG H1299 cells, yellow represent HPRT1-
FLAG and purple represents the TNFAIP8L1. There are 561,181 and 138 unique genes 
respectively.  
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Table 6. A comprehensive list of all 138 genes that encode for protein interactors with TNFAIP8L1 
arranged by their ENSEMBL nomenclature. 
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Figure 11. Summary of 138 genes for unique protein interactors with TNFAIP8L1 as they relate to 
biological processes using the PANTHER classification system for analysis. 
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TNFAIP8L1 does not interact directly with DVL3 or FBXW5. 
 Validation of expected protein-protein interactions with TNFAIP8L1 from 
research previously published (Chatr-Aryamontri et al., 2017; Ha et al., 2014) was not 
verified through mammalian two-hybrid assay. Relative interaction was calculated as a 
ratio of firefly luciferase activity to Renilla luciferase activity and reported as individual 
points representing replicates (Figure 13, Supplementary Figure 1). Renilla luciferase 
activity is encoded for in the pBIND vector allowing stable activity of Renilla to be used 
Figure 12 (A) Network that relates genes and proteins with known TNFAIP8L1 
interactions to putative protein interactions from mass spectrometry data using Ingenuity 
Pathways software. Dotted lines represent indirect interactions and solid lines represent 
direct interactions. White shapes are presumably primary interactors and grey shapes, 
secondary interactors. Network Shapes defined in key to the right of the figure. (B) Cell 
Cycle interactors singled out from other interactors (Xia 2015, 2018). (C) Circadian 
rhythm interactors singled out from other interactors (Xia 2015, 2018). 
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as an internal control. This activity is independent of interactions and allows for 
normalization between samples with different cell numbers and transfection efficiencies. 
Controls were performed with 4 replicates each and experimental wells had 8 replicates 
for each. TNFAIP8L1 was expected to interact with DVL3 and FBXW5, but our results 
did not support evidence of an interaction. FBXW5 was validated as an interactor with 
TNFAIP8L1 (Ha et al., 2014) and DVL3 was previously determined to be a potential 
interactor, but not validated (Rual et al., 2005). 
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Figure 13.  Results of mammalian two-hybrid assay. The fusion construct VP16-MyoD + 
GAL4-Id was used as a positive control. Relative interaction was calculated as a ratio of firefly 
luciferase activity to Renilla luciferase activity. Individual points represent replicates. Controls 
were performed with 4 replicates each and experimental wells had 8 replicates for each. No 
significant interaction between experimental constructs was seen in either experiment. 
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DISCUSSION 
 
 
 
With cancer near the top of the most prevalent diseases list for diagnoses and fatalities 
and poised to stay there, it is critical to understand the processes that govern it. An 
expanded understanding of tumorigenesis pathways and proteins that act in these 
pathways can guide us to new prevention tactics as well as to better aimed treatment 
options, which are highly sought after today. Previous studies of TNFAIP8L1 since its 
discovery in 2008 have left it relatively uncharacterized, and surrounded by many 
questions about its role in tumorigenesis and immunity. The putative protein interactors 
identified in this study provide a place to start when looking at its role and functions as a 
tumor suppressor. 
 There were 138 putative protein interactors with TNFAIP8L1 identified in this 
study (Table 6, Supplementary Table 1). A gene ontology study using the PANTHER 
(Protein ANalysis THrough Evolutionary Relationships) classification system revealed 
that there was a wide variety of biological processes implicated by interactors. The 
majority encoded for proteins involved in cellular processes (27%), followed by  
metabolic processes (18.9%), biological regulation (12.9%), cellular component 
organization (12.4%), multicellular organismal processes (7.7%), localization (7.7%), 
response to stimulus (6.9%), developmental processes (3.9%),locomotion (1.3%), 
immune system processes (0.9%) and reproduction (0.4%) (Figure 11). The cellular 
processes portion was further broken down into cell communication (54.3%), cellular 
component movement (20%), cell cycle regulation (11.4%), cell growth (5.7%), cell 
recognition (5.7%), and cytokinesis (2.9%). The data suggest the TNFAIP8L1 plays a 
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role in many different biological processes and pathways particularly those involving 
cellular processes such as cell communication and the cell cycle (Figure 12b). It is also 
interesting to note that only 0.9% of genes encoding proteins that interacted with 
TNFAIP8L1 control immune system processes, as it is believed that the TNFAIP8 gene 
family plays a role in immunity. 
 There were several genes of interest that were pulled out including melanoma-
associated antigen 4 (MAGEA4) and angiomotin (AMOT) (Figure 12a). MAGEA4 
encodes for the following proteins C9JK50, C9JIR1, Q1RN33, C9JZJ5, P43358, 
Q4V9T5, C9J9C2 pulled out in the mass spectrometry analysis of interactors. The 
MAGE-A gene family is expressed in numerous solid tumors, but silent in normal tissues 
except for male germline cells, which do not carry human leukocyte antigen (HLA) 
molecules. The proteins encoded for by the MAGE-A family are recognized by cytotoxic 
T-lymphocytes and allow for an immune response against tumor tissue (Hamosh, Scott, 
Amberger, Valle, & McKusick, 2000). In a study from 2000,  28% of patients with 
Hodgkin’s lymphoma expressed MAGEA4 indicating that MAGEA4 may be involved in 
Hodgkin’s lymphoma and a target for immunotherapy (Chambost et al., 2000).  
 Angiomotin (AMOT) is believed to play a role in the formation of new blood 
vessels, a process termed angiogenesis, and its regulation. Angiogenesis is necessary for 
tumors to grow and is therefore a topic of interest in tumorigenesis studies. AMOT has 
also been implicated in WNT signaling pathways, which is key for regulating 
development and previously associated with cancer (Z. Li et al., 2012). The WNT 
pathway is involved in signaling to the disheveled protein family, which includes DVL3. 
This link between TNFAIP8L1, AMOT, the WNT pathway and DVL3 could be 
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significant in understanding the underlying mechanisms of tumorigenesis and how 
TNFAIP8L1 plays a role.  
 Another interactor of interest was Neuronal PAS Domain Protein 2 (NPAS2), as it 
is associated circadian rhythm pathways (Figure 12c) and related genes (DeBruyne, 
Weaver, & Reppert, 2007; Landgraf, Wang, Diemer, & Welsh, 2016). The circadian 
clock is an internal time keeping system that regulates physiological processes and 
ultimately rhythms in gene expression that alter metabolism and behavior. Circadian 
rhythms regulate processes that alter physical, mental and behavioral changes. The 
rhythms can be disrupted and disruptions are linked to an increased risk of cancer 
development. In 2001, the Fred Hutchinson Cancer Research center showed nurses who 
regularly work the night shift were more likely to be diagnosed with cancer (Engel, 2014) 
and 10 years ago the International Agency for research on cancer classified night shift 
work as carcinogenic. While there is link between circadian disruption and cancer, as 
well as TNFAIP8L1 and circadian rhythm pathways, the mechanism of the links are 
unknown. TNFAIP8L1 may be playing a role in this pathway and its regulation in 
tumorigenesis.    
 These putative protein interactions, once validated, will lead to increased 
understanding of protein interaction pathways regulating the mechanism of tumorigenesis 
and ultimately the TNFAIP8L1 binding partners may serve as potential partners for 
future drug therapy and cancer prevention/treatment options. 
The mammalian two-hybrid validations in this experiment did not support our 
hypothesis or previous data suggesting FBXW5 and DVL3 interact directly with 
TNFAIP8L1. Issues validating interactors may be because they are not directly binding 
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TNFAIP8L1, but are part of a larger complex of proteins, or it is also possible that our 
system does not allow for post translational modifications to occur that are required for 
binding. Conversely, there could be post translational modifications occurring that are not 
true to biological function. 
In the future validation of putative TNAIP8L1 protein interactors could be 
performed using mammalian two-hybrid assays, but considerations of the systems 
shortcomings should be considered. A proximity ligation assay or other means of 
visualizing interactions such as bimolecular fluorescence complementation may be 
necessary. Performing a similar protein interaction study with TNFAIP8, TNFAIP8L2, 
and TNFAIP8L3 would be beneficial in increasing our understanding of the gene family, 
but also elucidate possible pathways to study for the individual members. Validated 
interactions should lead into mutagenesis studies to identify specific binding domains of 
TNFAIP8L1 and its binding partner as a way to identify possible clinical benefits. 
Previous studies have shown that TNFAIP8L1 plays a role in tumorigenesis and this 
current study asking what pathways it was involved with and through which protein 
interactions has revealed a large list of interactors to be validated and further studied. The 
importance of elucidating the function of TNFAIP8L1 lies in its importance as a tumor 
suppressor, as it could lead to new avenues of study and eventually target specific 
treatments for cancer. 
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Supplementary Figure 1.  Results of mammalian two-hybrid assay. The fusion construct 
VP16-MyoD + GAL4-Id was used as a positive control. Relative interaction was calculated as 
a ratio of firefly luciferase activity to Renilla luciferase activity. Individual points represent 
replicates. Controls were performed with 4 replicates each and experimental wells had 8 
replicates for each. No significant interaction between experimental constructs was seen in 
either experiment. 
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Gene stable ID Gene start (bp) 
Gene end 
(bp) Gene description 
Chromosome/scaffold 
name Gene name 
ENSG00000179869 48171458 48647496 
ATP binding cassette 
subfamily A member 13 
[Source:HGNC 
Symbol;Acc:HGNC:14638] 
7 ABCA13 
ENSG00000073734 168922938 169031322 
ATP binding cassette 
subfamily B member 11 
[Source:HGNC 
Symbol;Acc:HGNC:42] 
2 ABCB11 
ENSG00000281179 21717808 21718245  15 AC135068.8 
ENSG00000127507 14732393 14778541 
adhesion G protein-coupled 
receptor E2 [Source:HGNC 
Symbol;Acc:HGNC:3337] 
19 ADGRE2 
ENSG00000205336 57610652 57665580 
adhesion G protein-coupled 
receptor G1 [Source:HGNC 
Symbol;Acc:HGNC:4512] 
16 ADGRG1 
ENSG00000053371 19303965 19312146 
aldo-keto reductase family 7 
member A2 [Source:HGNC 
Symbol;Acc:HGNC:389] 
1 AKR7A2 
ENSG00000282988 26195595 26199293  6 AL031777.3 
ENSG00000132746 67662162 67681200 
aldehyde dehydrogenase 3 
family member B2 
[Source:HGNC 
Symbol;Acc:HGNC:411] 
11 ALDH3B2 
ENSG00000126016 112774503 112840815 angiomotin [Source:HGNC Symbol;Acc:HGNC:17810] X AMOT 
ENSG00000136250 36512949 36724549 
acyloxyacyl hydrolase 
[Source:HGNC 
Symbol;Acc:HGNC:548] 
7 AOAH 
ENSG00000107863 24583609 24723668 
Rho GTPase activating 
protein 21 [Source:HGNC 
Symbol;Acc:HGNC:23725] 
10 ARHGAP21 
ENSG00000064787 53936777 54070594 
breast carcinoma amplified 
sequence 1 [Source:HGNC 
Symbol;Acc:HGNC:974] 
20 BCAS1 
ENSG00000169594 83255903 83284714 basonuclin 1 [Source:HGNC Symbol;Acc:HGNC:1081] 15 BNC1 
ENSG00000175573 65916808 65919117 
chromosome 11 open 
reading frame 68 
[Source:HGNC 
Symbol;Acc:HGNC:28801] 
11 C11orf68 
ENSG00000260220 136249971 136306901 
coiled-coil domain 
containing 187 
[Source:HGNC 
Symbol;Acc:HGNC:30942] 
9 CCDC187 
ENSG00000140326 42723544 42737128 codanin 1 [Source:HGNC Symbol;Acc:HGNC:1713] 15 CDAN1 
ENSG00000130177 114234887 114272723 
cell division cycle 16 
[Source:HGNC 
Symbol;Acc:HGNC:1720] 
13 CDC16 
ENSG00000123219 65517766 65563171 
centromere protein K 
[Source:HGNC 
Symbol;Acc:HGNC:29479] 
5 CENPK 
ENSG00000126001 35455164 35519280 
centrosomal protein 250 
[Source:HGNC 
Symbol;Acc:HGNC:1859] 
20 CEP250 
ENSG00000120051 104353764 104455090 
cilia and flagella associated 
protein 58 [Source:HGNC 
Symbol;Acc:HGNC:26676] 
10 CFAP58 
ENSG00000164309 79689877 79800240 
cardiomyopathy associated 5 
[Source:HGNC 
Symbol;Acc:HGNC:14305] 
5 CMYA5 
ENSG00000138767 77713387 77819615 CCR4-NOT transcription complex subunit 6 like 4 CNOT6L 
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[Source:HGNC 
Symbol;Acc:HGNC:18042] 
ENSG00000165078 67422038 67746385 
carboxypeptidase A6 
[Source:HGNC 
Symbol;Acc:HGNC:17245] 
8 CPA6 
ENSG00000203710 207496147 207641765 
complement C3b/C4b 
receptor 1 (Knops blood 
group) [Source:HGNC 
Symbol;Acc:HGNC:2334] 
1 CR1 
ENSG00000142544 51097606 51108370 
cytosolic thiouridylase 
subunit 1 [Source:HGNC 
Symbol;Acc:HGNC:29590] 
19 CTU1 
ENSG00000139990 69050881 69153150 
DDB1 and CUL4 associated 
factor 5 [Source:HGNC 
Symbol;Acc:HGNC:20224] 
14 DCAF5 
ENSG00000156136 70992538 71030914 
deoxycytidine kinase 
[Source:HGNC 
Symbol;Acc:HGNC:2704] 
4 DCK 
ENSG00000177030 644233 706715 
DEAF1, transcription factor 
[Source:HGNC 
Symbol;Acc:HGNC:14677] 
11 DEAF1 
ENSG00000163214 38797729 38875934 
DExH-box helicase 57 
[Source:HGNC 
Symbol;Acc:HGNC:20086] 
2 DHX57 
ENSG00000116544 34865436 34929585 
DLG associated protein 3 
[Source:HGNC 
Symbol;Acc:HGNC:30368] 
1 DLGAP3 
ENSG00000007174 11598431 11969748 
dynein axonemal heavy 
chain 9 [Source:HGNC 
Symbol;Acc:HGNC:2953] 
17 DNAH9 
ENSG00000128512 111726110 112206411 
dedicator of cytokinesis 4 
[Source:HGNC 
Symbol;Acc:HGNC:19192] 
7 DOCK4 
ENSG00000088387 98793429 99086625 
dedicator of cytokinesis 9 
[Source:HGNC 
Symbol;Acc:HGNC:14132] 
13 DOCK9 
ENSG00000113719 172834275 172952685 
endoplasmic reticulum-golgi 
intermediate compartment 1 
[Source:HGNC 
Symbol;Acc:HGNC:29205] 
5 ERGIC1 
ENSG00000070367 57200507 57269008 
exocyst complex component 
5 [Source:HGNC 
Symbol;Acc:HGNC:10696] 
14 EXOC5 
ENSG00000174137 1617915 1684302 
family with sequence 
similarity 53 member A 
[Source:HGNC 
Symbol;Acc:HGNC:31860] 
4 FAM53A 
ENSG00000116120 222570536 222656337 
phenylalanyl-tRNA 
synthetase beta subunit 
[Source:HGNC 
Symbol;Acc:HGNC:17800] 
2 FARSB 
ENSG00000196159 125316399 125492932 
FAT atypical cadherin 4 
[Source:HGNC 
Symbol;Acc:HGNC:23109] 
4 FAT4 
ENSG00000007933 171090877 171117819 
flavin containing 
monooxygenase 3 
[Source:HGNC 
Symbol;Acc:HGNC:3771] 
1 FMO3 
ENSG00000113327 162000057 162162977 
gamma-aminobutyric acid 
type A receptor gamma2 
subunit [Source:HGNC 
Symbol;Acc:HGNC:4087] 
5 GABRG2 
ENSG00000154252 241776825 241804208 
galactose-3-O-
sulfotransferase 2 
[Source:HGNC 
Symbol;Acc:HGNC:24869] 
2 GAL3ST2 
ENSG00000276126 241799063 241804208 
galactose-3-O-
sulfotransferase 2 
[Source:HGNC 
Symbol;Acc:HGNC:24869] 
CHR_HSCHR2_3_CTG15 GAL3ST2 
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ENSG00000155511 153489615 153813869 
glutamate ionotropic 
receptor AMPA type subunit 
1 [Source:HGNC 
Symbol;Acc:HGNC:4571] 
5 GRIA1 
ENSG00000120251 157204182 157366075 
glutamate ionotropic 
receptor AMPA type subunit 
2 [Source:HGNC 
Symbol;Acc:HGNC:4572] 
4 GRIA2 
ENSG00000125675 123184153 123490915 
glutamate ionotropic 
receptor AMPA type subunit 
3 [Source:HGNC 
Symbol;Acc:HGNC:4573] 
X GRIA3 
ENSG00000152578 105609994 105982092 
glutamate ionotropic 
receptor AMPA type subunit 
4 [Source:HGNC 
Symbol;Acc:HGNC:4574] 
11 GRIA4 
ENSG00000187166 48328980 48330279 
H1 histone family member 
N, testis specific 
[Source:HGNC 
Symbol;Acc:HGNC:24893] 
12 H1FNT 
ENSG00000246705 14774383 14778002 
H2A histone family member 
J [Source:HGNC 
Symbol;Acc:HGNC:14456] 
12 H2AFJ 
ENSG00000105968 44826791 44848083 
H2A histone family member 
V [Source:HGNC 
Symbol;Acc:HGNC:20664] 
7 H2AFV 
ENSG00000188486 119093854 119095467 
H2A histone family member 
X [Source:HGNC 
Symbol;Acc:HGNC:4739] 
11 H2AFX 
ENSG00000164032 99948086 99950388 
H2A histone family member 
Z [Source:HGNC 
Symbol;Acc:HGNC:4741] 
4 H2AFZ 
ENSG00000164508 25726132 25726527 
histone cluster 1 H2A family 
member a [Source:HGNC 
Symbol;Acc:HGNC:18729] 
6 HIST1H2AA 
ENSG00000278463 26033176 26033568 
histone cluster 1 H2A family 
member b [Source:HGNC 
Symbol;Acc:HGNC:4734] 
6 HIST1H2AB 
ENSG00000180573 26124145 26139116 
histone cluster 1 H2A family 
member c [Source:HGNC 
Symbol;Acc:HGNC:4733] 
6 HIST1H2AC 
ENSG00000196866 26198851 26199243 
histone cluster 1 H2A family 
member d [Source:HGNC 
Symbol;Acc:HGNC:4729] 
6 HIST1H2AD 
ENSG00000277075 26216975 26217483 
histone cluster 1 H2A family 
member e [Source:HGNC 
Symbol;Acc:HGNC:4724] 
6 HIST1H2AE 
ENSG00000196787 27133042 27135291 
histone cluster 1 H2A family 
member g [Source:HGNC 
Symbol;Acc:HGNC:4737] 
6 HIST1H2AG 
ENSG00000274997 27147129 27147515 
histone cluster 1 H2A family 
member h [Source:HGNC 
Symbol;Acc:HGNC:13671] 
6 HIST1H2AH 
ENSG00000196747 27808199 27808701 
histone cluster 1 H2A family 
member i [Source:HGNC 
Symbol;Acc:HGNC:4725] 
6 HIST1H2AI 
ENSG00000276368 27814354 27814740 
histone cluster 1 H2A family 
member j [Source:HGNC 
Symbol;Acc:HGNC:4727] 
6 HIST1H2AJ 
ENSG00000275221 27837947 27838339 
histone cluster 1 H2A family 
member k [Source:HGNC 
Symbol;Acc:HGNC:4726] 
6 HIST1H2AK 
ENSG00000276903 27865355 27865747 
histone cluster 1 H2A family 
member l [Source:HGNC 
Symbol;Acc:HGNC:4730] 
6 HIST1H2AL 
ENSG00000278677 27892757 27893149 
histone cluster 1 H2A family 
member m [Source:HGNC 
Symbol;Acc:HGNC:4735] 
6 HIST1H2AM 
ENSG00000203812 149842188 149842736 histone cluster 2 H2A family member a3 [Source:HGNC 1 HIST2H2AA3 
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Symbol;Acc:HGNC:4736] 
ENSG00000272196 149851061 149851624 
histone cluster 2 H2A family 
member a4 [Source:HGNC 
Symbol;Acc:HGNC:29668] 
1 HIST2H2AA4 
ENSG00000184260 149886975 149887364 
histone cluster 2 H2A family 
member c [Source:HGNC 
Symbol;Acc:HGNC:4738] 
1 HIST2H2AC 
ENSG00000181218 228456979 228457873 
histone cluster 3 H2A 
[Source:HGNC 
Symbol;Acc:HGNC:20507] 
1 HIST3H2A 
ENSG00000135486 54280193 54287088 
heterogeneous nuclear 
ribonucleoprotein A1 
[Source:HGNC 
Symbol;Acc:HGNC:5031] 
12 HNRNPA1 
ENSG00000163913 129440036 129520507 
intraflagellar transport 122 
[Source:HGNC 
Symbol;Acc:HGNC:13556] 
3 IFT122 
ENSG00000270505 22160431 22160868 
immunoglobulin heavy 
variable 1/OR15-1 (non-
functional) [Source:HGNC 
Symbol;Acc:HGNC:5563] 
15 IGHV1OR15-1 
ENSG00000270467 33802764 33803217 
immunoglobulin heavy 
variable 3/OR16-12 (non-
functional) [Source:HGNC 
Symbol;Acc:HGNC:5636] 
16 IGHV3OR16-12 
ENSG00000149503 62123973 62153163 
inner centromere protein 
[Source:HGNC 
Symbol;Acc:HGNC:6058] 
11 INCENP 
ENSG00000188487 15112424 15247208 
INSC, spindle orientation 
adaptor protein 
[Source:HGNC 
Symbol;Acc:HGNC:33116] 
11 INSC 
ENSG00000168264 234604269 234609525 
interferon regulatory factor 2 
binding protein 2 
[Source:HGNC 
Symbol;Acc:HGNC:21729] 
1 IRF2BP2 
ENSG00000276289 7816675 7829926 
potassium voltage-gated 
channel subfamily E 
regulatory subunit 1B 
[Source:HGNC 
Symbol;Acc:HGNC:52280] 
21 KCNE1B 
ENSG00000197705 32672671 32773062 
kelch like family member 14 
[Source:HGNC 
Symbol;Acc:HGNC:29266] 
18 KLHL14 
ENSG00000055609 152134922 152436005 
lysine methyltransferase 2C 
[Source:HGNC 
Symbol;Acc:HGNC:13726] 
7 KMT2C 
ENSG00000135480 52232520 52252186 keratin 7 [Source:HGNC Symbol;Acc:HGNC:6445] 12 KRT7 
ENSG00000141068 27456470 27626438 
kinase suppressor of ras 1 
[Source:HGNC 
Symbol;Acc:HGNC:6465] 
17 KSR1 
ENSG00000133067 202193901 202319781 
leucine rich repeat 
containing G protein-
coupled receptor 6 
[Source:HGNC 
Symbol;Acc:HGNC:19719] 
1 LGR6 
ENSG00000167210 46476972 46657220 
lipoxygenase homology 
domains 1 [Source:HGNC 
Symbol;Acc:HGNC:26521] 
18 LOXHD1 
ENSG00000147381 151912509 151925170 
MAGE family member A4 
[Source:HGNC 
Symbol;Acc:HGNC:6802] 
X MAGEA4 
ENSG00000196547 90902218 90922584 
mannosidase alpha class 2A 
member 2 [Source:HGNC 
Symbol;Acc:HGNC:6825] 
15 MAN2A2 
ENSG00000168906 85539165 85545280 
methionine 
adenosyltransferase 2A 
[Source:HGNC 
Symbol;Acc:HGNC:6904] 
2 MAT2A 
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ENSG00000258839 89912119 89920977 
melanocortin 1 receptor 
[Source:HGNC 
Symbol;Acc:HGNC:6929] 
16 MC1R 
ENSG00000183019 7676628 7679826 
mast cell expressed 
membrane protein 1 
[Source:HGNC 
Symbol;Acc:HGNC:27291] 
19 MCEMP1 
ENSG00000175221 867630 893218 
mediator complex subunit 16 
[Source:HGNC 
Symbol;Acc:HGNC:17556] 
19 MED16 
ENSG00000176624 51174550 51218304 
mex-3 RNA binding family 
member C [Source:HGNC 
Symbol;Acc:HGNC:28040] 
18 MEX3C 
ENSG00000135517 56449502 56469166 
major intrinsic protein of 
lens fiber [Source:HGNC 
Symbol;Acc:HGNC:7103] 
12 MIP 
ENSG00000171843 20341665 20622543 
MLLT3, super elongation 
complex subunit 
[Source:HGNC 
Symbol;Acc:HGNC:7136] 
9 MLLT3 
ENSG00000074071 1771890 1773155 
mitochondrial ribosomal 
protein S34 [Source:HGNC 
Symbol;Acc:HGNC:16618] 
16 MRPS34 
ENSG00000197535 52307283 52529050 myosin VA [Source:HGNC Symbol;Acc:HGNC:7602] 15 MYO5A 
ENSG00000066248 232878686 233013272 
neuronal guanine nucleotide 
exchange factor 
[Source:HGNC 
Symbol;Acc:HGNC:7807] 
2 NGEF 
ENSG00000055044 202265716 202303666 
NOP58 ribonucleoprotein 
[Source:HGNC 
Symbol;Acc:HGNC:29926] 
2 NOP58 
ENSG00000170485 100820152 100996829 
neuronal PAS domain 
protein 2 [Source:HGNC 
Symbol;Acc:HGNC:7895] 
2 NPAS2 
ENSG00000148200 124517275 124771310 
nuclear receptor subfamily 6 
group A member 1 
[Source:HGNC 
Symbol;Acc:HGNC:7985] 
9 NR6A1 
ENSG00000122126 129539849 129592561 
OCRL, inositol 
polyphosphate-5-
phosphatase [Source:HGNC 
Symbol;Acc:HGNC:8108] 
X OCRL 
ENSG00000167332 4680171 4697854 
olfactory receptor family 51 
subfamily E member 2 
[Source:HGNC 
Symbol;Acc:HGNC:15195] 
11 OR51E2 
ENSG00000172464 56641466 56642471 
olfactory receptor family 5 
subfamily AP member 2 
[Source:HGNC 
Symbol;Acc:HGNC:15258] 
11 OR5AP2 
ENSG00000181752 56159394 56160317 
olfactory receptor family 8 
subfamily K member 5 
[Source:HGNC 
Symbol;Acc:HGNC:15315] 
11 OR8K5 
ENSG00000187950 29412474 29497686 
ovochymase 1 
[Source:HGNC 
Symbol;Acc:HGNC:23080] 
12 OVCH1 
ENSG00000110811 6828410 6839851 
prolyl 3-hydroxylase 3 
[Source:HGNC 
Symbol;Acc:HGNC:19318] 
12 P3H3 
ENSG00000163110 94451857 94668227 
PDZ and LIM domain 5 
[Source:HGNC 
Symbol;Acc:HGNC:17468] 
4 PDLIM5 
ENSG00000185238 20387530 20509294 
protein arginine 
methyltransferase 3 
[Source:HGNC 
Symbol;Acc:HGNC:30163] 
11 PRMT3 
ENSG00000135406 49293252 49298686 peripherin [Source:HGNC Symbol;Acc:HGNC:9461] 12 PRPH 
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ENSG00000100804 23016543 23035230 
proteasome subunit beta 5 
[Source:HGNC 
Symbol;Acc:HGNC:9542] 
14 PSMB5 
ENSG00000108469 75626845 75667189 
RecQ like helicase 5 
[Source:HGNC 
Symbol;Acc:HGNC:9950] 
17 RECQL5 
ENSG00000143344 183636085 183928531 
ral guanine nucleotide 
dissociation stimulator like 1 
[Source:HGNC 
Symbol;Acc:HGNC:30281] 
1 RGL1 
ENSG00000080345 151409883 151508013 
replication timing regulatory 
factor 1 [Source:HGNC 
Symbol;Acc:HGNC:23207] 
2 RIF1 
ENSG00000137522 71928701 71997597 
ring finger protein 121 
[Source:HGNC 
Symbol;Acc:HGNC:21070] 
11 RNF121 
ENSG00000198863 42980565 42993690 
RUN domain containing 1 
[Source:HGNC 
Symbol;Acc:HGNC:25418] 
17 RUNDC1 
ENSG00000196218 38433699 38587564 
ryanodine receptor 1 
[Source:HGNC 
Symbol;Acc:HGNC:10483] 
19 RYR1 
ENSG00000137872 47184101 47774223 
semaphorin 6D 
[Source:HGNC 
Symbol;Acc:HGNC:16770] 
15 SEMA6D 
ENSG00000163904 185582496 185633551 
SUMO1/sentrin/SMT3 
specific peptidase 2 
[Source:HGNC 
Symbol;Acc:HGNC:23116] 
3 SENP2 
ENSG00000140264 43777087 43802589 
small EDRK-rich factor 2 
[Source:HGNC 
Symbol;Acc:HGNC:10757] 
15 SERF2 
ENSG00000170364 4303304 4317567 
SET domain and mariner 
transposase fusion gene 
[Source:HGNC 
Symbol;Acc:HGNC:10762] 
3 SETMAR 
ENSG00000100014 24270817 24417740 
sperm antigen with calponin 
homology and coiled-coil 
domains 1 like 
[Source:HGNC 
Symbol;Acc:HGNC:29022] 
22 SPECC1L 
ENSG00000138600 50702266 50765808 
signal peptide peptidase like 
2A [Source:HGNC 
Symbol;Acc:HGNC:30227] 
15 SPPL2A 
ENSG00000159433 42575659 42720981 
StAR related lipid transfer 
domain containing 9 
[Source:HGNC 
Symbol;Acc:HGNC:19162] 
15 STARD9 
ENSG00000164506 147204425 147390476 
syntaxin binding protein 5 
[Source:HGNC 
Symbol;Acc:HGNC:19665] 
6 STXBP5 
ENSG00000144455 3700814 4467281 
sulfatase modifying factor 1 
[Source:HGNC 
Symbol;Acc:HGNC:20376] 
3 SUMF1 
ENSG00000156787 123041968 123152153 
TBC1 domain family 
member 31 [Source:HGNC 
Symbol;Acc:HGNC:30888] 
8 TBC1D31 
ENSG00000176946 241584405 241637449 
THAP domain containing 4 
[Source:HGNC 
Symbol;Acc:HGNC:23187] 
2 THAP4 
ENSG00000115705 1374223 1543711 
thyroid peroxidase 
[Source:HGNC 
Symbol;Acc:HGNC:12015] 
2 TPO 
ENSG00000277603 1372594 1540021 
thyroid peroxidase 
[Source:HGNC 
Symbol;Acc:HGNC:12015] 
CHR_HSCHR2_4_CTG1 TPO 
ENSG00000128881 42738734 42920809 
tau tubulin kinase 2 
[Source:HGNC 
Symbol;Acc:HGNC:19141] 
15 TTBK2 
ENSG00000177398 42062959 42143453 uromodulin like 1 21 UMODL1 
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[Source:HGNC 
Symbol;Acc:HGNC:12560] 
ENSG00000109189 52590972 52659335 
ubiquitin specific peptidase 
46 [Source:HGNC 
Symbol;Acc:HGNC:20075] 
4 USP46 
ENSG00000143952 63892146 64019072 
VPS54, GARP complex 
subunit [Source:HGNC 
Symbol;Acc:HGNC:18652] 
2 VPS54 
ENSG00000167716 1716523 1738599 
WD repeat domain 81 
[Source:HGNC 
Symbol;Acc:HGNC:26600] 
17 WDR81 
ENSG00000276021 1716523 1738610 
WD repeat domain 81 
[Source:HGNC 
Symbol;Acc:HGNC:26600] 
CHR_HSCHR17_1_CTG2 WDR81 
ENSG00000142784 27234516 27308633 
WD and tetratricopeptide 
repeats 1 [Source:HGNC 
Symbol;Acc:HGNC:29175] 
1 WDTC1 
ENSG00000241127 39566376 39610320 
Yae1 domain containing 1 
[Source:HGNC 
Symbol;Acc:HGNC:24857] 
7 YAE1D1 
ENSG00000140836 72782885 73891871 
zinc finger homeobox 3 
[Source:HGNC 
Symbol;Acc:HGNC:777] 
16 ZFHX3 
ENSG00000196646 12163064 12189881 
zinc finger protein 136 
[Source:HGNC 
Symbol;Acc:HGNC:12920] 
19 ZNF136 
ENSG00000267680 44094339 44109886 
zinc finger protein 224 
[Source:HGNC 
Symbol;Acc:HGNC:13017] 
19 ZNF224 
ENSG00000160094 33256545 33300719 
zinc finger protein 362 
[Source:HGNC 
Symbol;Acc:HGNC:18079] 
1 ZNF362 
ENSG00000180938 124973298 124979389 
zinc finger protein 572 
[Source:HGNC 
Symbol;Acc:HGNC:26758] 
8 ZNF572 
ENSG00000188171 20620061 20661596 
zinc finger protein 626 
[Source:HGNC 
Symbol;Acc:HGNC:30461] 
19 ZNF626 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. Summary of 138 unique genes interactors pulled out in mass 
spectrometry.  
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